Q-omics provides the consensus-scored PFKFB2 profile across patient tissues and cancer cell-line models. PFKFB2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, PFKFB2 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, PFKFB2 protein abundance shows 19,203 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ESCA, KIRC, and GBM as cancer lineages where PFKFB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PFKFB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PFKFB2 survival associations across molecular data types. PFKFB2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PFKFB2 RNA expression–survival associations across cancer types. High PFKFB2 expression shows unfavorable associations in ESCA, LIHC, OV, LGG and LUSC, but favorable associations in UCEC. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify ESCA as the clearest survival context for PFKFB2 RNA expression.
This table summarizes PFKFB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PFKFB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PFKFB2 shows lower tumor expression in KIRC, THCA and LUAD and higher tumor expression in BLCA, HNSC and LIHC. The KIRC box plot shows higher PFKFB2 RNA expression in normal versus tumor tissue (log2 FC = −2.134, t-test p < 0.001).
This table shows molecular features associated with PFKFB2 in patient tissues and cancer cell lines. In patient samples, PFKFB2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PFKFB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
